Journal of Health Care for the Poor and Underserved volume 17, issue 4, P808-820 2006 DOI: 10.1353/hpu.2006.0138 View full text
|
|
Share
Jane Zara

Abstract: Advocates of drug price restrictions in the U.S. argue that pharmaceutical companies operate in an unregulated market, free to charge whatever price the market will bear. The pharmaceutical industry insists that these large profits are justified for investments toward discovering new life saving medicines. As innovation wanes, marketing costs soar, and drug profits rise, public interest advocates and state leaders are challenging this justification. This article examines current problems associated with the ab…

expand abstract